Adverse effects of immune checkpoint inhibitors used to treat melanoma and other cancer
Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained approval for the treatment of metastatic melanoma and advanced/refractory non small-cell lung cancers and metastatic renal cancer. Besides their efficacy profile, these immune targeted agent...
Gespeichert in:
| Veröffentlicht in: | La Presse médicale (1983) 2017-09, Vol.46 (9), p.808-817 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | fre |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 817 |
|---|---|
| container_issue | 9 |
| container_start_page | 808 |
| container_title | La Presse médicale (1983) |
| container_volume | 46 |
| creator | Jacquin-Porretaz, Claire Nardin, Charlée Puzenat, Eve Roche-Kubler, Blandine Aubin, François |
| description | Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained approval for the treatment of metastatic melanoma and advanced/refractory non small-cell lung cancers and metastatic renal cancer. Besides their efficacy profile, these immune targeted agents also generate immune-related adverse events that may be life threatening if not anticipated and managed appropriately. This new family of dysimmune toxicities remains largely unknown to the broad oncology community. We propose here some practical guidelines for the oncologist to help in the clinical care of patients under immune checkpoint molecules. |
| doi_str_mv | 10.1016/j.lpm.2017.05.032 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1917361471</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1917361471</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-b9c608dbd6ab942af268bb1c34b7111f85a55d9081ae1a7323c9fe23efdaef3f3</originalsourceid><addsrcrecordid>eNo1kM1KxDAYRYMgzjj6AG4kSzet-ZJpmy6HwT8YcKO4LPn5wnRsmpqkgm_vgOPqbg6Xcy8hN8BKYFDfH8ph8iVn0JSsKpngZ2TJOYiC8aZekMuUDoxxWDftBVlwWUvRVnJJPjb2G2NCis6hyYkGR3vv5xGp2aP5nEI_ZtqP-173OcRE54SW5kBzRJWpx0GNwSuqRktD3mOkRo0G4xU5d2pIeH3KFXl_fHjbPhe716eX7WZXTBwgF7o1NZNW21rpds2V47XUGoxY6wYAnKxUVdmWSVAIqhFcmNYhF-isQiecWJG7v94phq8ZU-58nwwORy0Mc-qghUbUx9lwRG9P6Kw92m6KvVfxp_s_Q_wCIVJhaw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1917361471</pqid></control><display><type>article</type><title>Adverse effects of immune checkpoint inhibitors used to treat melanoma and other cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Jacquin-Porretaz, Claire ; Nardin, Charlée ; Puzenat, Eve ; Roche-Kubler, Blandine ; Aubin, François</creator><creatorcontrib>Jacquin-Porretaz, Claire ; Nardin, Charlée ; Puzenat, Eve ; Roche-Kubler, Blandine ; Aubin, François ; Comité de suivi des effets secondaires des immunothérapies anti-cancéreuses(CSESIAC)</creatorcontrib><description>Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained approval for the treatment of metastatic melanoma and advanced/refractory non small-cell lung cancers and metastatic renal cancer. Besides their efficacy profile, these immune targeted agents also generate immune-related adverse events that may be life threatening if not anticipated and managed appropriately. This new family of dysimmune toxicities remains largely unknown to the broad oncology community. We propose here some practical guidelines for the oncologist to help in the clinical care of patients under immune checkpoint molecules.</description><identifier>EISSN: 2213-0276</identifier><identifier>DOI: 10.1016/j.lpm.2017.05.032</identifier><identifier>PMID: 28683958</identifier><language>fre</language><publisher>France</publisher><subject>Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Renal Cell - drug therapy ; Carcinoma, Renal Cell - genetics ; Carcinoma, Renal Cell - pathology ; CTLA-4 Antigen - antagonists & inhibitors ; CTLA-4 Antigen - genetics ; Genes, cdc - drug effects ; Guideline Adherence ; Immunotoxins - adverse effects ; Immunotoxins - therapeutic use ; Kidney Neoplasms - drug therapy ; Kidney Neoplasms - genetics ; Kidney Neoplasms - pathology ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Melanoma - drug therapy ; Melanoma - genetics ; Neoplasm Metastasis ; Programmed Cell Death 1 Receptor - antagonists & inhibitors ; Programmed Cell Death 1 Receptor - genetics ; Skin Neoplasms - drug therapy ; Skin Neoplasms - genetics ; Skin Neoplasms - pathology</subject><ispartof>La Presse médicale (1983), 2017-09, Vol.46 (9), p.808-817</ispartof><rights>Copyright © 2017 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28683958$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jacquin-Porretaz, Claire</creatorcontrib><creatorcontrib>Nardin, Charlée</creatorcontrib><creatorcontrib>Puzenat, Eve</creatorcontrib><creatorcontrib>Roche-Kubler, Blandine</creatorcontrib><creatorcontrib>Aubin, François</creatorcontrib><creatorcontrib>Comité de suivi des effets secondaires des immunothérapies anti-cancéreuses(CSESIAC)</creatorcontrib><title>Adverse effects of immune checkpoint inhibitors used to treat melanoma and other cancer</title><title>La Presse médicale (1983)</title><addtitle>Presse Med</addtitle><description>Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained approval for the treatment of metastatic melanoma and advanced/refractory non small-cell lung cancers and metastatic renal cancer. Besides their efficacy profile, these immune targeted agents also generate immune-related adverse events that may be life threatening if not anticipated and managed appropriately. This new family of dysimmune toxicities remains largely unknown to the broad oncology community. We propose here some practical guidelines for the oncologist to help in the clinical care of patients under immune checkpoint molecules.</description><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Carcinoma, Renal Cell - genetics</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>CTLA-4 Antigen - antagonists & inhibitors</subject><subject>CTLA-4 Antigen - genetics</subject><subject>Genes, cdc - drug effects</subject><subject>Guideline Adherence</subject><subject>Immunotoxins - adverse effects</subject><subject>Immunotoxins - therapeutic use</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Kidney Neoplasms - genetics</subject><subject>Kidney Neoplasms - pathology</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - pathology</subject><subject>Melanoma - drug therapy</subject><subject>Melanoma - genetics</subject><subject>Neoplasm Metastasis</subject><subject>Programmed Cell Death 1 Receptor - antagonists & inhibitors</subject><subject>Programmed Cell Death 1 Receptor - genetics</subject><subject>Skin Neoplasms - drug therapy</subject><subject>Skin Neoplasms - genetics</subject><subject>Skin Neoplasms - pathology</subject><issn>2213-0276</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kM1KxDAYRYMgzjj6AG4kSzet-ZJpmy6HwT8YcKO4LPn5wnRsmpqkgm_vgOPqbg6Xcy8hN8BKYFDfH8ph8iVn0JSsKpngZ2TJOYiC8aZekMuUDoxxWDftBVlwWUvRVnJJPjb2G2NCis6hyYkGR3vv5xGp2aP5nEI_ZtqP-173OcRE54SW5kBzRJWpx0GNwSuqRktD3mOkRo0G4xU5d2pIeH3KFXl_fHjbPhe716eX7WZXTBwgF7o1NZNW21rpds2V47XUGoxY6wYAnKxUVdmWSVAIqhFcmNYhF-isQiecWJG7v94phq8ZU-58nwwORy0Mc-qghUbUx9lwRG9P6Kw92m6KvVfxp_s_Q_wCIVJhaw</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Jacquin-Porretaz, Claire</creator><creator>Nardin, Charlée</creator><creator>Puzenat, Eve</creator><creator>Roche-Kubler, Blandine</creator><creator>Aubin, François</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201709</creationdate><title>Adverse effects of immune checkpoint inhibitors used to treat melanoma and other cancer</title><author>Jacquin-Porretaz, Claire ; Nardin, Charlée ; Puzenat, Eve ; Roche-Kubler, Blandine ; Aubin, François</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-b9c608dbd6ab942af268bb1c34b7111f85a55d9081ae1a7323c9fe23efdaef3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2017</creationdate><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Carcinoma, Renal Cell - genetics</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>CTLA-4 Antigen - antagonists & inhibitors</topic><topic>CTLA-4 Antigen - genetics</topic><topic>Genes, cdc - drug effects</topic><topic>Guideline Adherence</topic><topic>Immunotoxins - adverse effects</topic><topic>Immunotoxins - therapeutic use</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Kidney Neoplasms - genetics</topic><topic>Kidney Neoplasms - pathology</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - pathology</topic><topic>Melanoma - drug therapy</topic><topic>Melanoma - genetics</topic><topic>Neoplasm Metastasis</topic><topic>Programmed Cell Death 1 Receptor - antagonists & inhibitors</topic><topic>Programmed Cell Death 1 Receptor - genetics</topic><topic>Skin Neoplasms - drug therapy</topic><topic>Skin Neoplasms - genetics</topic><topic>Skin Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jacquin-Porretaz, Claire</creatorcontrib><creatorcontrib>Nardin, Charlée</creatorcontrib><creatorcontrib>Puzenat, Eve</creatorcontrib><creatorcontrib>Roche-Kubler, Blandine</creatorcontrib><creatorcontrib>Aubin, François</creatorcontrib><creatorcontrib>Comité de suivi des effets secondaires des immunothérapies anti-cancéreuses(CSESIAC)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>La Presse médicale (1983)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jacquin-Porretaz, Claire</au><au>Nardin, Charlée</au><au>Puzenat, Eve</au><au>Roche-Kubler, Blandine</au><au>Aubin, François</au><aucorp>Comité de suivi des effets secondaires des immunothérapies anti-cancéreuses(CSESIAC)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adverse effects of immune checkpoint inhibitors used to treat melanoma and other cancer</atitle><jtitle>La Presse médicale (1983)</jtitle><addtitle>Presse Med</addtitle><date>2017-09</date><risdate>2017</risdate><volume>46</volume><issue>9</issue><spage>808</spage><epage>817</epage><pages>808-817</pages><eissn>2213-0276</eissn><abstract>Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained approval for the treatment of metastatic melanoma and advanced/refractory non small-cell lung cancers and metastatic renal cancer. Besides their efficacy profile, these immune targeted agents also generate immune-related adverse events that may be life threatening if not anticipated and managed appropriately. This new family of dysimmune toxicities remains largely unknown to the broad oncology community. We propose here some practical guidelines for the oncologist to help in the clinical care of patients under immune checkpoint molecules.</abstract><cop>France</cop><pmid>28683958</pmid><doi>10.1016/j.lpm.2017.05.032</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 2213-0276 |
| ispartof | La Presse médicale (1983), 2017-09, Vol.46 (9), p.808-817 |
| issn | 2213-0276 |
| language | fre |
| recordid | cdi_proquest_miscellaneous_1917361471 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - genetics Carcinoma, Renal Cell - pathology CTLA-4 Antigen - antagonists & inhibitors CTLA-4 Antigen - genetics Genes, cdc - drug effects Guideline Adherence Immunotoxins - adverse effects Immunotoxins - therapeutic use Kidney Neoplasms - drug therapy Kidney Neoplasms - genetics Kidney Neoplasms - pathology Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Melanoma - drug therapy Melanoma - genetics Neoplasm Metastasis Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - genetics Skin Neoplasms - drug therapy Skin Neoplasms - genetics Skin Neoplasms - pathology |
| title | Adverse effects of immune checkpoint inhibitors used to treat melanoma and other cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T13%3A23%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adverse%20effects%20of%20immune%20checkpoint%20inhibitors%20used%20to%20treat%20melanoma%20and%20other%20cancer&rft.jtitle=La%20Presse%20m%C3%A9dicale%20(1983)&rft.au=Jacquin-Porretaz,%20Claire&rft.aucorp=Comit%C3%A9%20de%20suivi%20des%20effets%20secondaires%20des%20immunoth%C3%A9rapies%20anti-canc%C3%A9reuses(CSESIAC)&rft.date=2017-09&rft.volume=46&rft.issue=9&rft.spage=808&rft.epage=817&rft.pages=808-817&rft.eissn=2213-0276&rft_id=info:doi/10.1016/j.lpm.2017.05.032&rft_dat=%3Cproquest_pubme%3E1917361471%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1917361471&rft_id=info:pmid/28683958&rfr_iscdi=true |